Your browser doesn't support javascript.
loading
NALCN-mediated sodium influx confers metastatic prostate cancer cell invasiveness.
Folcher, Antoine; Gordienko, Dmitri; Iamshanova, Oksana; Bokhobza, Alexandre; Shapovalov, George; Kannancheri-Puthooru, Dheeraj; Mariot, Pascal; Allart, Laurent; Desruelles, Emilie; Spriet, Corentin; Diez, Raquel; Oullier, Thibauld; Marionneau-Lambot, Séverine; Brisson, Lucie; Geraci, Sandra; Impheng, Hathaichanok; Lehen'kyi, V'yacheslav; Haustrate, Aurélien; Mihalache, Adriana; Gosset, Pierre; Chadet, Stéphanie; Retif, Stéphanie; Laube, Maryline; Sobilo, Julien; Lerondel, Stéphanie; Villari, Giulia; Serini, Guido; Pla, Alessandra Fiorio; Roger, Sébastien; Fromont-Hankard, Gaelle; Djamgoz, Mustafa; Clezardin, Philippe; Monteil, Arnaud; Prevarskaya, Natalia.
Afiliação
  • Folcher A; Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
  • Gordienko D; Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
  • Iamshanova O; Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
  • Bokhobza A; Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
  • Shapovalov G; Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
  • Kannancheri-Puthooru D; Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
  • Mariot P; Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
  • Allart L; Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
  • Desruelles E; Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
  • Spriet C; TISBio, Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), CNRS, UMR 8576, Université de Lille, Lille, France.
  • Diez R; Cell Physiology Research Group, Department of Physiology, University of Extremadura, Cáceres, Spain.
  • Oullier T; Cancéropôle du Grand Ouest, Plateforme In Vivo, Nantes, France.
  • Marionneau-Lambot S; Cancéropôle du Grand Ouest, Plateforme In Vivo, Nantes, France.
  • Brisson L; Inserm UMR1069, Nutrition Croissance et Cancer, University of Tours, Tours, France.
  • Geraci S; Univ Lyon, Université Claude Bernard Lyon 1, Inserm UMR 1033 LYOS, Lyon, France.
  • Impheng H; Department of Physiology, Faculty of Medical science, Naresuan University, Phitsanulok, Thailand.
  • Lehen'kyi V; Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
  • Haustrate A; Inserm U1003, Laboratory of Excellence, Ion Channels Science and Therapeutics, Equipe Labellisée par la Ligue Nationale Contre le Cancer, GIS ONCO Lille, University of Lille, Lille, France.
  • Mihalache A; Service d'Anatomie et de Cytologie Pathologiques, Groupement des Hôpitaux de l'Université Catholique de Lille, Lille, France.
  • Gosset P; Service d'Anatomie et de Cytologie Pathologiques, Groupement des Hôpitaux de l'Université Catholique de Lille, Lille, France.
  • Chadet S; EA4245 Transplantation, Immunology, Inflammation, University of Tours, Tours, France.
  • Retif S; PHENOMIN-TAAM, CNRS UPS44, Centre d'Imagerie du Petit Animal (CIPA), 3B rue de la Férollerie, Orléans, France.
  • Laube M; PHENOMIN-TAAM, CNRS UPS44, Centre d'Imagerie du Petit Animal (CIPA), 3B rue de la Férollerie, Orléans, France.
  • Sobilo J; PHENOMIN-TAAM, CNRS UPS44, Centre d'Imagerie du Petit Animal (CIPA), 3B rue de la Férollerie, Orléans, France.
  • Lerondel S; PHENOMIN-TAAM, CNRS UPS44, Centre d'Imagerie du Petit Animal (CIPA), 3B rue de la Férollerie, Orléans, France.
  • Villari G; Department of Oncology, University of Torino School of Medicine, Candiolo, Italy.
  • Serini G; Candiolo Cancer Institute - Fondazione del Piemonte per l'Oncologia (FPO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Italy.
  • Pla AF; Department of Oncology, University of Torino School of Medicine, Candiolo, Italy.
  • Roger S; Candiolo Cancer Institute - Fondazione del Piemonte per l'Oncologia (FPO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Italy.
  • Fromont-Hankard G; Department of Life Science and Systems Biology, University of Torino, Torino, Italy.
  • Djamgoz M; EA4245 Transplantation, Immunology, Inflammation, University of Tours, Tours, France.
  • Clezardin P; Inserm UMR1069, Nutrition Croissance et Cancer, University of Tours, Tours, France.
  • Monteil A; Department of Pathology, CHRU de Tours, Tours, France.
  • Prevarskaya N; Department of Life Sciences, Imperial College London, London, UK.
EMBO J ; 42(13): e112198, 2023 07 03.
Article em En | MEDLINE | ID: mdl-37278161
There is growing evidence that ion channels are critically involved in cancer cell invasiveness and metastasis. However, the molecular mechanisms of ion signaling promoting cancer behavior are poorly understood and the complexity of the underlying remodeling during metastasis remains to be explored. Here, using a variety of in vitro and in vivo techniques, we show that metastatic prostate cancer cells acquire a specific Na+ /Ca2+ signature required for persistent invasion. We identify the Na+ leak channel, NALCN, which is overexpressed in metastatic prostate cancer, as a major initiator and regulator of Ca2+ oscillations required for invadopodia formation. Indeed, NALCN-mediated Na+ influx into cancer cells maintains intracellular Ca2+ oscillations via a specific chain of ion transport proteins including plasmalemmal and mitochondrial Na+ /Ca2+ exchangers, SERCA and store-operated channels. This signaling cascade promotes activity of the NACLN-colocalized proto-oncogene Src kinase, actin remodeling and secretion of proteolytic enzymes, thus increasing cancer cell invasive potential and metastatic lesions in vivo. Overall, our findings provide new insights into an ion signaling pathway specific for metastatic cells where NALCN acts as persistent invasion controller.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Sódio Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Revista: EMBO J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Sódio Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Revista: EMBO J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: França